Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERKINELMER, INC.

(PKI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
172.11(c) 170.16(c) 174.46(c) 179.3(c) 182.23(c) Last
2 004 552 949 799 1 123 110 1 232 231 1 199 155 Volume
+4.73% -1.13% +2.53% +2.77% +1.63% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4 590 M - -
Net income 2021 902 M - -
Net Debt 2021 2 055 M - -
P/E ratio 2021 22,7x
Yield 2021 0,15%
Sales 2022 3 952 M - -
Net income 2022 557 M - -
Net Debt 2022 2 496 M - -
P/E ratio 2022 39,1x
Yield 2022 0,15%
Capitalization 20 426 M 20 426 M -
EV / Sales 2021 4,90x
EV / Sales 2022 5,80x
Nbr of Employees 14 000
Free-Float 99,7%
More Financials
Company
PerkinElmer Inc. is a provider of products, services and solutions for the diagnostics, life sciences and applied markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. Its Discovery & Analytical Solutions segment serves the life sciences and applied markets. Through the Diagnostics Segment, it offers instruments, reagents, assay platforms, and software to hospitals,... 
More about the company
Ratings of PerkinElmer, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about PERKINELMER, INC.
07/28Perkinelmer, Inc Expands KRAS Oncology Drug Discovery Assays with New Ready-t..
CI
07/27PERKINELMER : to Acquire Antibody and Reagent Leader BioLegend Transformative de..
PU
07/27PERKINELMER INC : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
07/27PERKINELMER : Evercore ISI Adjusts Price Target on PerkinElmer to $190 From $175..
MT
07/27PERKINELMER : JPMorgan Adjusts Price Target for PerkinElmer to $168 From $155, M..
MT
07/27PERKINELMER : Baird Adjusts PerkinElmer PT to $183 From $150, Maintains Outperfo..
MT
07/26Health Care Down On Cyclical Bias -- Health Care Roundup
DJ
07/26PERKINELMER : to pay $5.25B for antibody maker BioLegend
AQ
07/26PERKINELMER : to Buy BioLegend for $5.25 Billion as Second-Quarter Results Top S..
MT
07/26PerkinElmer to buy antibodies maker BioLegend for about $5.3 billion
RE
07/26PERKINELMER : to Buy BioLegend for $5.25 Billion in Cash and Stock
MT
07/26PERKINELMER : BioLegend Acquisition Infographic
PU
07/26PERKINELMER : Q2 2021 Earnings Presentation
PU
07/26PERKINELMER : to Acquire BioLegend
PU
07/26PERKINELMER : Q2 Earnings Snapshot
AQ
More news
News in other languages on PERKINELMER, INC.
06/16WALL STREET STOCK EXCHANGE : Cómo podrían afectar los datos de ayer a la polític..
04/07DGAP-HV : Fresenius Medical Care AG & Co. KGaA: -4-
04/07DGAP-HV : Fresenius Medical Care AG & Co. KGaA: -2-
03/30PERKINELMER : Horizon Discovery erweitert sein Genmodulations-Portfolio um die b..
03/30PERKINELMER : Horizon Discovery enrichit son portefeuille de modulation génétiqu..
More news
Analyst Recommendations on PERKINELMER, INC.
More recommendations
Stock Trading Strategies
PERKINELMER, INC. - 05/17
Technically solid
BUY
More Stock Trading Analysis
Chart PERKINELMER, INC.
Duration : Period :
PerkinElmer, Inc. Technical Analysis Chart | PKI | US7140461093 | MarketScreener
Technical analysis trends PERKINELMER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 182,23 $
Average target price 176,42 $
Spread / Average Target -3,19%
EPS Revisions
Managers and Directors
Prahlad Ramadhar Singh President, CEO, COO & Director
James M. Mock Chief Financial Officer & Senior Vice President
Alexis Platon Michas Non-Executive Chairman
Joel S. Goldberg Secretary, SVP-Administration & General Counsel
Peter Barrett Independent Director
Sector and Competitors